Inhalation delivery of nucleic acid gene therapies in preclinical drug development

References

• High KA. Turning genes into medicines—what have we learned from gene therapy drug development in the past decade? Nat Commun. 2020;11(1):5821. doi: 10.1038/s41467-020-19507-0
   PubMed Web of Science ®Google Scholar
• Gottlieb S. Statement from FDA commissioner Scott Gottlieb, M.D. and Peter Marks, M.D., Ph.D., director of the center for biologics Evaluation and research on new policies to advance development of safe and effective cell and gene therapies [Internet]. FDA; 2019 [cited 2023 Apr 25]. Available from: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-and-peter-marks-md-phd-director-center-biologics
   Google Scholar
• FDA Office of Tissues and Advanced Therapies (OTAT). Approved cellular and gene therapy products [Internet]. FDA. FDA; 2023 [cited 2023 Apr 25]. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
   Google Scholar
• Becerra X. Food and Drug administration: statement of organization, functions, and delegations of authority. Fed Regist. 2022;87:58806–58807.
   Google Scholar
• Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs). Guidance for industry. Docket Number 2008-D-0205. [Internet]. U.S. Departent of Health and Human Services, Food and Drug Adminstration. Center for Biologics Evaluation and Research; 2020 [cited 2023 Apr 18]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemistry-manufacturing-and-control-cmc-information-human-gene-therapy-investigational-new-drug
   Google Scholar
• Zogg H, Singh R, Ro S. Current advances in RNA therapeutics for human diseases. Int J Mol Sci. 2022;23(5):2736. doi: 10.3390/ijms23052736
   PubMed Web of Science ®Google Scholar
• Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022;23:265–280.
   PubMed Web of Science ®Google Scholar
• Scholz C, Wagner E. Therapeutic plasmid DNA versus siRNA delivery: common and different tasks for synthetic carriers. Drug Deliv Res Eur. 2012;161:554–565. doi: 10.1016/j.jconrel.2011.11.014
   Google Scholar
• Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19(10):673–694. doi: 10.1038/s41573-020-0075-7
   PubMed Web of Science ®Google Scholar
• Hu B, Zhong L, Weng Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5(1):101. doi: 10.1038/s41392-020-0207-x
   PubMed Web of Science ®Google Scholar
• Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov. 2017;16(3):181–202. doi: 10.1038/nrd.2016.199
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203–222. doi: 10.1038/nrd.2016.246
   PubMed Web of Science ®Google Scholar
• Chow MYT, Qiu Y, Lam JKW. Inhaled RNA therapy: from promise to reality. Trends Pharmacol Sci. 2020;41:715–729.
   PubMed Web of Science ®Google Scholar
• Bulcha JT, Wang Y, Ma H, et al. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6(1):53. doi: 10.1038/s41392-021-00487-6
   PubMed Web of Science ®Google Scholar
• McCarron A, Cmielewski P, Drysdale V, et al. Effective viral-mediated lung gene therapy: is airway surface preparation necessary? Gene Ther. 2023;30(6):469–477. doi: 10.1038/s41434-022-00332-7
   PubMed Web of Science ®Google Scholar
• Srivastava A, Mallela KMG, Deorkar N, et al. Manufacturing challenges and rational formulation development for AAV viral vectors. J Pharm Sci. 2021;110(7):2609–2624. doi: 10.1016/j.xphs.2021.03.024
   PubMed Web of Science ®Google Scholar
• Wang H, Qin L, Zhang X, et al. Mechanisms and challenges of nanocarriers as non-viral vectors of therapeutic genes for enhanced pulmonary delivery. J Controlled Release. 2022;352:970–993. doi: 10.1016/j.jconrel.2022.10.061
   PubMed Web of Science ®Google Scholar
• Huang T, Gao J, Cai L, et al. Treating pulmonary fibrosis with non-viral gene therapy: from bench to bedside. Pharmaceutics. 2022;14(4):813. doi: 10.3390/pharmaceutics14040813
   PubMed Web of Science ®Google Scholar
• Chuan D, Jin T, Fan R, et al. Chitosan for gene delivery: methods for improvement and applications. Adv Colloid Interface Sci. 2019;268:25–38. doi: 10.1016/j.cis.2019.03.007
   PubMed Web of Science ®Google Scholar
• Hopkins C, Javius-Jones K, Wang Y, et al. Combinations of chemo-, immuno-, and gene therapies using nanocarriers as a multifunctional drug platform. Expert Opin Drug Deliv. 2022;19(10):1337–1349. doi: 10.1080/17425247.2022.2112569
   PubMed Web of Science ®Google Scholar
• Burdett T, Nuseibeh S. Changing trends in the development of AAV-based gene therapies: a meta-analysis of past and present therapies. Gene Ther. 2023;30(3–4):323–335. doi: 10.1038/s41434-022-00363-0
   PubMed Web of Science ®Google Scholar
• Gautam A, Waldrep JC, Densmore CL. Aerosol gene therapy. Mol Biotechnol. 2003;23:51–60. doi: 10.1385/MB:23:1:51
   PubMed Web of Science ®Google Scholar
• Sui H, Xu X, Su Y, et al. Gene therapy for cystic fibrosis: challenges and prospects. Front Pharmacol. 2022;13:1015926. doi: 10.3389/fphar.2022.1015926
   PubMed Web of Science ®Google Scholar
• Cooney A, McCray P, Sinn P. Cystic fibrosis gene therapy: looking back, looking forward. Genes. 2018;9(11):538. doi: 10.3390/genes9110538
   PubMed Web of Science ®Google Scholar
• Rowe SM, Zuckerman JB, Dorgan D, et al. Inhaled mRNA therapy for treatment of cystic fibrosis: interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2023;22(4):656–664. S1569-1993(23)00112-1. doi: 10.1016/j.jcf.2023.04.008
   PubMedGoogle Scholar
• Tepper JS, Kuehl PJ, Cracknell S, et al. Symposium summary: “breathe in, breathe out, its easy: what you need to know about developing inhaled drugs. Int J Toxicol. 2016;35(4):376–392. doi: 10.1177/1091581815624080
   PubMed Web of Science ®Google Scholar
• Preclinical Assessment of Investigational Cellular and Gene Therapy Products. Docket number FDA-2012-D-1038. [Internet]. U.S. Departent of Health and Human Services, Food and Drug Adminstration. Center for Biologics Evaluation and Research; 2019 [cited 2023 May 1]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/preclinical-assessment-investigational-cellular-and-gene-therapy-products
   Google Scholar
• Ehrmann S, Schmid O, Darquenne C, et al. Innovative preclinical models for pulmonary drug delivery research. Expert Opin Drug Deliv. 2020;17(4):463–478. doi: 10.1080/17425247.2020.1730807
   PubMed Web of Science ®Google Scholar
• Selo MA, Sake JA, Kim KJ, et al. In vitro and ex vivo models in inhalation biopharmaceutical research — advances, challenges and future perspectives. Adv Drug Deliv Rev. 2021;177:113862. doi: 10.1016/j.addr.2021.113862
   PubMed Web of Science ®Google Scholar
• Ramamurthy RM, Atala A, Porada CD, et al. Organoids and microphysiological systems: promising models for accelerating AAV gene therapy studies. Front Immunol. 2022;13:1011143. doi: 10.3389/fimmu.2022.1011143
   PubMed Web of Science ®Google Scholar
• Stein SW, Thiel CG. The history of therapeutic aerosols: a chronological review. J Aerosol Med Pulm Drug Deliv. 2016;30:20–41. doi: 10.1089/jamp.2016.1297
   PubMed Web of Science ®Google Scholar
• Pires Ferreira D, Gruntman AM, Flotte TR. Gene therapy for alpha-1 antitrypsin deficiency: an update. Expert Opin Biol Ther. 2023;23(3):283–291. doi: 10.1080/14712598.2023.2183771
   PubMed Web of Science ®Google Scholar
• El-Husseini ZW, Gosens R, Dekker F, et al. The genetics of asthma and the promise of genomics-guided drug target discovery. Lancet Respir Med. 2020;8(10):1045–1056. doi: 10.1016/S2213-2600(20)30363-5
   PubMed Web of Science ®Google Scholar
• Lee WH, Loo CY, Ghadiri M, et al. The potential to treat lung cancer via inhalation of repurposed drugs. Adv Drug Deliv Rev. 2018;133:107–130. doi: 10.1016/j.addr.2018.08.012
   PubMed Web of Science ®Google Scholar
• Martin AR, Moore CP, Finlay WH. Models of deposition, pharmacokinetics, and intersubject variability in respiratory drug delivery. Expert Opin Drug Deliv. 2018;15(12):1175–1188. doi: 10.1080/17425247.2018.1544616
   PubMed Web of Science ®Google Scholar
• Ruge CC, Kirch J, Lehr CM. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges. Lancet Respir Med. 2013;1:402–413. doi: 10.1016/S2213-2600(13)70072-9
   PubMed Web of Science ®Google Scholar
• Loira-Pastoriza C, Todoroff J, Vanbever R. Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev. 2014;75:81–91. doi: 10.1016/j.addr.2014.05.017
   PubMed Web of Science ®Google Scholar
• Hastedt JE, Bäckman P, Clark AR, et al. Scope and relevance of a pulmonary biopharmaceutical classification system AAPS/FDA/USP workshop March 16-17th, 2015 in Baltimore, MD. Am Assoc Pharm Sci Open. 2016;2:1. doi: 10.1186/s41120-016-0005-2
   Google Scholar
• Kubczak M, Michlewska S, Bryszewska M, et al. Nanoparticles for local delivery of siRNA in lung therapy. Adv Drug Deliv Rev. 2021;179:114038. doi: 10.1016/j.addr.2021.114038
   PubMed Web of Science ®Google Scholar
• Chow MYT, Chang RYK, Chan H-K. Inhalation delivery technology for genome-editing of respiratory diseases. Adv Drug Deliv Rev. 2021;168:217–228. doi: 10.1016/j.addr.2020.06.001
   PubMed Web of Science ®Google Scholar
• Gomes Dos Reis L, Svolos M, Hartwig B, et al. Inhaled gene delivery: a formulation and delivery approach. Expert Opin Drug Deliv. 2017;14:319–330. doi: 10.1080/17425247.2016.1214569
   PubMed Web of Science ®Google Scholar
• Finlay WH. The mechanics of inhaled pharmaceutical aerosols : an introduction. San Diego: Academic Press; 2019. doi: 10.1016/B978-0-08-102749-3.00001-4
   Google Scholar
• International Commission on Radiological Protection. Human respiratory tract model for radiological protection: a report of a task group of the International Commission on Radiological protection. Oxford, Eng : Tarrytown (N.Y): published for the International Commission on Radiological Protection by Pergamon; 1994.
   Google Scholar
• Hofmann W. Regional deposition: deposition models. J Aerosol Med Pulm Drug Deliv. 2020;33(5):239–248. doi: 10.1089/jamp.2020.29031.wh
   PubMed Web of Science ®Google Scholar
• Miller FJ, Asgharian B, Schroeter JD, et al. Improvements and additions to the multiple path particle dosimetry model. J Aerosol Sci. 2016;99:14–26. doi: 10.1016/j.jaerosci.2016.01.018
   Web of Science ®Google Scholar
• Ruzycki CA, Pawluski D, Wong EYL, et al. Provocative dose determination for methacholine challenge test aerosols through in vitro – in silico methods. J Aerosol Sci. 2023;171:106184. doi: 10.1016/j.jaerosci.2023.106184
   Web of Science ®Google Scholar
• Kim N, Duncan GA, Hanes J, et al. Barriers to inhaled gene therapy of obstructive lung diseases: a review. J Controlled Release. 2016;240:465–488. doi: 10.1016/j.jconrel.2016.05.031
   PubMed Web of Science ®Google Scholar
• Griesenbach U, Alton EWFW. Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. Adv Drug Deliv Rev. 2009;61:128–139. doi: 10.1016/j.addr.2008.09.010
   PubMed Web of Science ®Google Scholar
• Ari A, Fink JB. Recent advances in aerosol devices for the delivery of inhaled medications. Expert Opin Drug Deliv. 2020;17(2):133–144. doi: 10.1080/17425247.2020.1712356
   PubMed Web of Science ®Google Scholar
• Martin AR, Finlay WH. Nebulizers for drug delivery to the lungs. Expert Opin Drug Deliv. 2015;12(6):889–900. doi: 10.1517/17425247.2015.995087
   PubMed Web of Science ®Google Scholar
• Weers JG, Miller DP. Formulation design of dry powders for inhalation. J Pharm Sci. 2015;104(10):3259–3288. doi: 10.1002/jps.24574
   PubMed Web of Science ®Google Scholar
• Vehring R, Snyder H, Lechuga-Ballesteros D. Spray Drying. In: Ohtake S, Izutsu K-i, and Lechuga-Ballesteros D, editors. Drying Technologies for Biotechnology and Pharmaceutical Applicatoins. Weinheim, Germany: Wiley-VCH; 2020. p.179–216. doi: 10.1002/9783527802104.ch7
   Google Scholar
• Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler technology: formulation development. AAPS Pharm Sci Tech. 2014;15(2):434–455. doi: 10.1208/s12249-013-0063-x
   PubMed Web of Science ®Google Scholar
• Conti DS, Bharatwaj B, Brewer D, et al. Propellant-based inhalers for the non-invasive delivery of genes via oral inhalation. J Controlled Release. 2012;157(3):406–417. doi: 10.1016/j.jconrel.2011.09.089
   PubMed Web of Science ®Google Scholar
• Carrigy NB, Chang RY, Leung SSY, et al. Anti-tuberculosis bacteriophage D29 delivery with a vibrating mesh nebulizer, Jet nebulizer, and soft mist inhaler. Pharm Res. 2017;34(10):2084–2096. doi: 10.1007/s11095-017-2213-4
   PubMed Web of Science ®Google Scholar
• Lentz YK, Anchordoquy TJ, Lengsfeld CS. Rationale for the selection of an aerosol delivery system for gene delivery. J Aerosol Med. 2006; 19(3):372–384. doi: 10.1089/jam.2006.19.372
   PubMedGoogle Scholar
• Deshpande D, Blanchard J, Srinivasan S, et al. Aerosolization of lipoplexes using AERx® pulmonary delivery system. AAPS PharmSci. 2002;4:12–21. doi: 10.1208/ps040313
   Google Scholar
• Arulmuthu ER, Williams DJ, Baldascini H, et al. Studies on aerosol delivery of plasmid DNA using a mesh nebulizer. Biotechnol Bioeng. 2007;98(5):939–955. doi: 10.1002/bit.21493
   PubMed Web of Science ®Google Scholar
• Gomes Dos Reis L, Svolos M, Moir LM, et al. Delivery of pDNA Polyplexes to bronchial and alveolar epithelial cells using a mesh nebulizer. Pharm Res. 2019;36:14. doi: 10.1007/s11095-018-2542-y
   Web of Science ®Google Scholar
• Lentz YK, Worden LR, Anchordoquy TJ, et al. Effect of jet nebulization on DNA: identifying the dominant degradation mechanism and mitigation methods. J Aerosol Sci. 2005;36(8):973–990. doi: 10.1016/j.jaerosci.2004.11.017
   Web of Science ®Google Scholar
• Catanese DJ, Fogg JM, Schrock DE, et al. Supercoiled minivector DNA resists shear forces associated with gene therapy delivery. Gene Ther. 2012;19(1):94–100. doi: 10.1038/gt.2011.77
   PubMed Web of Science ®Google Scholar
• Lengsfeld CS, Anchordoquy TJ. Shear‐induced degradation of plasmid DNA. J Pharm Sci. 2002;91(7):1581–1589. doi: 10.1002/jps.10140
   PubMed Web of Science ®Google Scholar
• Zabner J, Fasbender AJ, Moninger T, et al. Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem. 1995;270(32):18997–19007. doi: 10.1074/jbc.270.32.18997
   PubMed Web of Science ®Google Scholar
• Ibraheem D, Elaissari A, Fessi H. Gene therapy and DNA delivery systems. Int J Pharm. 2014;459(1–2):70–83. doi: 10.1016/j.ijpharm.2013.11.041
   PubMed Web of Science ®Google Scholar
• Banks GA, Roselli RJ, Chen R, et al. A model for the analysis of nonviral gene therapy. Gene Ther. 2003;10(20):1766–1775. doi: 10.1038/sj.gt.3302076
   PubMed Web of Science ®Google Scholar
• Emerson M, Renwick L, Tate S, et al. Transfection efficiency and toxicity following delivery of naked plasmid DNA and cationic lipid–DNA complexes to ovine lung segments. Mol Ther. 2003;8(4):646–653. doi: 10.1016/S1525-0016(03)00233-8
   PubMed Web of Science ®Google Scholar
• Ichikawa M, Muramatsu N, Matsunaga W, et al. Effects of inhalable gene transfection as a novel gene therapy for non-small cell lung cancer and malignant pleural mesothelioma. Sci Rep. 2022;12(1):8634. doi: 10.1038/s41598-022-12624-4
   PubMed Web of Science ®Google Scholar
• Woodside MT, García-García C, Block SM. Folding and unfolding single RNA molecules under tension. Curr Opin Chem Biol. 2008;12(6):640–646. doi: 10.1016/j.cbpa.2008.08.011
   PubMed Web of Science ®Google Scholar
• Bustamante C, Smith SB, Liphardt J, et al. Single-molecule studies of DNA mechanics. Curr Opin Struct Biol. 2000;10(3):279–285. doi: 10.1016/S0959-440X(00)00085-3
   PubMed Web of Science ®Google Scholar
• Tahara K, Hashimoto W, Takeuchi H. Inhalation properties and stability of nebulized naked siRNA solution for pulmonary therapy. Chem Pharm Bull (Tokyo). 2016;64:63–67. doi: 10.1248/cpb.c15-00615
   PubMed Web of Science ®Google Scholar
• Cortez-Jugo C, Masoumi S, Chan PPY, et al. Nebulization of siRNA for inhalation therapy based on a microfluidic surface acoustic wave platform. Ultrason Sonochem. 2022;88:106088. doi: 10.1016/j.ultsonch.2022.106088
   PubMed Web of Science ®Google Scholar
• Morgan BA, Manser M, Jeyanathan M, et al. Effect of shear stresses on adenovirus activity and aggregation during atomization to produce thermally stable vaccines by spray drying. ACS Biomater Sci Eng. 2020;6(7):4304–4313. doi: 10.1021/acsbiomaterials.0c00317
   PubMed Web of Science ®Google Scholar
• Roy CJ, Ault A, Sivasubramani SK, et al. Aerosolized adenovirus-vectored vaccine as an alternative vaccine delivery method. Respir Res. 2011;12(1):153. doi: 10.1186/1465-9921-12-153
   PubMed Web of Science ®Google Scholar
• Klein DM, Poortinga A, Verhoeven FM, et al. Degradation of lipid based drug delivery formulations during nebulization. Chem Phys. 2021;547:111192. doi: 10.1016/j.chemphys.2021.111192
   Web of Science ®Google Scholar
• Kim J, Jozic A, Lin Y, et al. Engineering lipid nanoparticles for enhanced intracellular delivery of mRNA through inhalation. ACS Nano. 2022;16(9):14792–14806. doi: 10.1021/acsnano.2c05647
   PubMedGoogle Scholar
• Phalen RF, Yeh HC, Prasad SB. Morphology of the respiratory tract. In: McClellan R Henderson R, editors. Concepts in inhalation toxicology. 2nd ed. Washington DC: Taylor & Francis; 1995. p. 129–149. doi: 10.1201/b14404-9
   Google Scholar
• Harkema JR, Plopper CG, Pinkerton KE. Comparative structure of the respiratory tract: airway architecture in humans and animals. In: Cohen M, Zelikoff J, and Schlesinger R, editors. Pulmonary Immunotoxicology. Boston (MA): Springer US; 2000. p. 1–59. doi: 10.1007/978-1-4615-4535-4_1
   Google Scholar
• Borgström L, Olsson B, Thorsson L. Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J Aerosol Med Off. 2006;19(4):473–483. doi: 10.1089/jam.2006.19.473
   PubMedGoogle Scholar
• Ruzycki CA, Yang M, Chan H-K, et al. Improved prediction of intersubject variability in extrathoracic aerosol deposition using algebraic correlations. Aerosol Sci Technol. 2017;51(6):667–673. doi: 10.1080/02786826.2017.1306640
   Web of Science ®Google Scholar
• Yang MY, Ruzycki CA, Verschuer J, et al. Examining the ability of empirical correlations to predict subject specific in vivo extrathoracic aerosol deposition during tidal breathing. Aerosol Sci Technol. 2017;51(3):363–376. doi: 10.1080/02786826.2016.1262532
   Web of Science ®Google Scholar
• Usmani OS, Roche N, Jenkins M, et al. Consistent pulmonary Drug delivery with whole lung deposition using the aerosphere inhaler: a review of the evidence. Int J Chron Obstruct Pulmon Dis. 2021;16:113–124. doi: 10.2147/COPD.S274846
   PubMed Web of Science ®Google Scholar
• Delvadia RR, Hindle M, Longest PW, et al. In vitro tests for aerosol deposition II: IVIVCs for different dry powder inhalers in normal adults. J Aerosol Med Pulm Drug Deliv. 2012;26:138–144. doi: 10.1089/jamp.2012.0975
   PubMed Web of Science ®Google Scholar
• Ruzycki CA, Finlay WH, Martin AR. Estimating clinically relevant measures of inhaled pharmaceutical aerosol performance with advanced in vitro and in silico methods. In: Narang A Mahato R, editors. Organ specific drug delivery and targeting to the lungs. CRC Press; 2022. p. 3–46. doi: 10.1201/9781003182566-2
   Google Scholar
• Weers JG, Miller DP, Tarara TE. Improved targeting of dry powder formulations of inhaled corticosteroids to children. Respir Drug Deliv. 2022;2022:1–8.
   Google Scholar
• Weers JG, Son YJ, Glusker M, et al. Idealhalers versus realhalers: is it possible to bypass deposition in the upper respiratory tract? J Aerosol Med Pulm Drug Deliv. 2019;32(2):55–69. doi: 10.1089/jamp.2018.1497
   PubMed Web of Science ®Google Scholar
• Farkas D, Thomas ML, Hassan A, et al. Near elimination of in vitro Predicted extrathoracic aerosol deposition in children using a spray-Dried Antibiotic formulation and pediatric air-jet DPI. Pharm Res. 2023;40(5):1193–1207. doi: 10.1007/s11095-022-03316-9
   PubMed Web of Science ®Google Scholar
• Holbrook LT, Longest PW. Validating CFD predictions of highly localized aerosol deposition in airway models: in vitro data and effects of surface properties. J Aerosol Sci. 2013;59:6–21. doi: 10.1016/j.jaerosci.2013.01.008
   Web of Science ®Google Scholar
• Lizal F, Elcner J, Jedelsky J, et al. The effect of oral and nasal breathing on the deposition of inhaled particles in upper and tracheobronchial airways. J Aerosol Sci. 2020;150:105649. doi: 10.1016/j.jaerosci.2020.105649
   PubMed Web of Science ®Google Scholar
• Ruzycki CA, Murphy B, Nathoo H, et al. Combined in vitro-in silico approach to predict deposition and pharmacokinetics of budesonide dry powder inhalers. Pharm Res. 2020;37(10):209. doi: 10.1007/s11095-020-02924-7
   PubMed Web of Science ®Google Scholar
• Tavernini S, Farina DJ, Martin AR, et al. Using filters to estimate regional lung deposition with dry powder inhalers. Pharm Res. 2021;38(9):1601–1613. doi: 10.1007/s11095-021-03082-0
   PubMed Web of Science ®Google Scholar
• Finlay WH, Farina DJ, Tavernini S, et al. In vitro estimation of tracheobronchial and alveolar doses using filters. Front Drug Deliv. 2022;2:1–7. doi: 10.3389/fddev.2022.901289
   Google Scholar
• Stocks J, Hislop AA. Structure and function of the respiratory system: developmental aspects and their relevance to aerosol therapy. In: Bisgaard H, O’Callaghan C Smaldone G, editors. Drug delivery to the lung. New York (NY): Marcel Dekker; 2002. p. 47–104. doi: 10.1201/b14022-4
   Google Scholar
• Cohen-Cymberknoh M, Kerem E, Ferkol T, et al. Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications. Thorax. 2013;68(12):1157–1162. doi: 10.1136/thoraxjnl-2013-203204
   PubMed Web of Science ®Google Scholar
• Martin AR. Regional deposition: targeting. J Aerosol Med Pulm Drug Deliv. 2021;34(1):1–10. doi: 10.1089/jamp.2021.29033.am
   PubMed Web of Science ®Google Scholar
• Schürch S, Gehr P, Im Hof V, et al. Surfactant displaces particles toward the epithelium in airways and alveoli. Respir Physiol. 1990;80(1):17–32. doi: 10.1016/0034-5687(90)90003-H
   PubMedGoogle Scholar
• Pangeni R, Meng T, Poudel S, et al. Airway mucus in pulmonary diseases: muco-adhesive and muco-penetrating particles to overcome the airway mucus barriers. Int J Pharm. 2023;634:122661. doi: 10.1016/j.ijpharm.2023.122661
   PubMedGoogle Scholar
• Hewitt RJ, Lloyd CM. Regulation of immune responses by the airway epithelial cell landscape. Nat Rev Immunol. 2021; 21(6):347–362. doi: 10.1038/s41577-020-00477-9
   PubMed Web of Science ®Google Scholar
• Laube BL. Aerosolized medications for gene and peptide therapy. Respir Care. 2015;60(6):806–824. doi: 10.4187/respcare.03554
   PubMed Web of Science ®Google Scholar
• Huffnagle GB, Dickson RP, Lukacs NW. The respiratory tract microbiome and lung inflammation: a two-way street. Mucosal Immunol. 2017; 10(2):299–306. doi: 10.1038/mi.2016.108
   PubMed Web of Science ®Google Scholar
• Capasso C, Hirvinen M, Cerullo V. Beyond gene delivery: strategies to engineer the surfaces of viral vectors. Biomedicines. 2013;1(1):3–16. doi: 10.3390/biomedicines1010003
   PubMedGoogle Scholar
• Lee AY, Cho M-H, Kim S. Recent advances in aerosol gene delivery systems using non-viral vectors for lung cancer therapy. Expert Opin Drug Deliv. 2019;16(7):757–772. doi: 10.1080/17425247.2019.1641083
   PubMed Web of Science ®Google Scholar
• Manunta MDI, McAnulty RJ, Tagalakis AD, et al. Nebulisation of receptor-targeted nanocomplexes for gene delivery to the airway epithelium. PLoS One. 2011;6(10):e26768. doi: 10.1371/journal.pone.0026768
   PubMed Web of Science ®Google Scholar
• Wolff RK, Dorato MA. Toxicologic testing of inhaled pharmaceutical aerosols. Crit Rev Toxicol. 1993;23(4):343–369. doi: 10.3109/10408449309104076
   PubMed Web of Science ®Google Scholar
• In: McClellan RO, Henderson RF, editors. Concepts in inhalation toxicology. 2nd ed. Washington DC: Taylor & Francis; 1995. doi: 10.1201/b14404
   Google Scholar
• Wolff RK. Toxicology studies for inhaled and nasal delivery. Mol Pharm. 2015;12(8):2688–2696. doi: 10.1021/acs.molpharmaceut.5b00146
   PubMedGoogle Scholar
• Alexander DJ, Collins CJ, Coombs DW, et al. Association of Inhalation Toxicologists (AIT) working party recommendation for standard delivered dose calculation and expression in non-clinical aerosol inhalation toxicology studies with pharmaceuticals. Inhal Toxicol. 2008;20(13):1179–1189. doi: 10.1080/08958370802207318
   PubMed Web of Science ®Google Scholar
• Kuehl PJ, Chand R, McDonald JD, et al. Pulmonary and regional deposition of nebulized and dry powder aerosols in ferrets. AAPS Pharm Sci Tech. 2019;20(6):242. doi: 10.1208/s12249-019-1382-3
   PubMed Web of Science ®Google Scholar
• Nadithe V, Rahamatalla M, Finlay WH, et al. Evaluation of nose-only aerosol inhalation chamber and comparison of experimental results with mathematical simulation of aerosol deposition in mouse lungs. J Pharm Sci. 2003;92(5):1066–1076. doi: 10.1002/jps.10379
   PubMed Web of Science ®Google Scholar
• McCarron A, Parsons D, Donnelley M. Animal and cell culture models for cystic fibrosis. Am J Pathol. 2021;191(2):228–242. doi: 10.1016/j.ajpath.2020.10.017
   PubMed Web of Science ®Google Scholar
• Yan Z, Stewart ZA, Sinn PL, et al. Ferret and pig models of cystic fibrosis: prospects and promise for gene therapy. Hum Gene Ther Clin Dev. 2015;26(1):38–49. doi: 10.1089/humc.2014.154
   PubMed Web of Science ®Google Scholar
• Sun X, Yi Y, Yan Z, et al. In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis. Sci Transl Med. 2019;11(485):11. doi: 10.1126/scitranslmed.aau7531
   Web of Science ®Google Scholar
• Gautam A, Densmore C, Waldrep J. Pulmonary cytokine responses associated with PEI–DNA aerosol gene therapy. Gene Ther. 2001;8(3):254–257. doi: 10.1038/sj.gt.3301369
   PubMed Web of Science ®Google Scholar
• Densmore CL, Orson FM, Xu B, et al. Aerosol delivery of robust polyethyleneimine– DNA complexes for gene therapy and genetic immunization. Mol Ther. 2000;1(2):180–188. doi: 10.1006/mthe.1999.0021
   PubMed Web of Science ®Google Scholar
• Bai X, Zhao G, Chen Q, et al. Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge. Sci Adv. 2022;8(25):eabn7162. doi: 10.1126/sciadv.abn7162
   PubMed Web of Science ®Google Scholar
• Lokugamage MP, Vanover D, Beyersdorf J, et al. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nat Biomed Eng. 2021;5(9):1059–1068. doi: 10.1038/s41551-021-00786-x
   PubMed Web of Science ®Google Scholar
• Patel AK, Kaczmarek JC, Bose S, et al. Inhaled nanoformulated mRNA polyplexes for protein production in lung epithelium. Adv Mater. 2019;31(8):1805116. doi: 10.1002/adma.201805116
   PubMed Web of Science ®Google Scholar
• Le Gall T, Berchel M, Davies L, et al. Aerosol-mediated non-viral lung gene therapy: the potential of aminoglycoside-based cationic liposomes. Pharmaceutics. 2021;14(1):25. doi: 10.3390/pharmaceutics14010025
   PubMed Web of Science ®Google Scholar
• Zamora-Avila DE, Zapata-Benavides P, Franco-Molina MA, et al. WT1 gene silencing by aerosol delivery of PEI–RNAi complexes inhibits B16-F10 lung metastases growth. Cancer Gene Ther. 2009;16(12):892–899. doi: 10.1038/cgt.2009.35
   PubMed Web of Science ®Google Scholar
• McIntyre C, Donnelley M, Rout-Pitt N, et al. Lobe-specific gene vector delivery to rat lungs using a miniature bronchoscope. Hum Gene Ther Methods. 2018;29(5):228–235. doi: 10.1089/hgtb.2018.050
   PubMed Web of Science ®Google Scholar
• Weiss DJ, Mutlu GM, Bonneau L, et al. Comparison of surfactant and perfluorochemical liquid enhanced adenovirus-mediated gene transfer in normal rat lung. Mol Ther J Am Soc Gene Ther. 2002;6(1):43–49. doi: 10.1006/mthe.2002.0632
   PubMed Web of Science ®Google Scholar
• Bisserier M, Mathiyalagan P, Zhang S, et al. Regulation of the methylation and expression levels of the BMPR2 gene by SIN3a as a novel therapeutic mechanism in pulmonary arterial hypertension. Circulation. 2021;144(1):52–73. doi: 10.1161/CIRCULATIONAHA.120.047978
   PubMed Web of Science ®Google Scholar
• Koehler DR, Frndova H, Leung K, et al. Aerosol delivery of an enhanced helper-dependent adenovirus formulation to rabbit lung using an intratracheal catheter. J Gene Med. 2005;7(11):1409–1420. doi: 10.1002/jgm.797
   PubMed Web of Science ®Google Scholar
• Aguero J, Ishikawa K, Hadri L, et al. Intratracheal gene delivery of SERCA2a ameliorates chronic post-capillary pulmonary hypertension. J Am Coll Cardiol. 2016;67(17):2032–2046. doi: 10.1016/j.jacc.2016.02.049
   PubMed Web of Science ®Google Scholar
• Cooney AL, Sinn PL. Intratracheal aerosolization of viral vectors to newborn pig airways. Biotechniques. 2020;68(5):235–239. doi: 10.2144/btn-2019-0150
   PubMed Web of Science ®Google Scholar
• Cao H, Machuca TN, Yeung JC, et al. Efficient gene delivery to pig airway epithelia and submucosal glands using helper-dependent adenoviral vectors. Mol Ther Nucleic Acids. 2013;2:e127. doi: 10.1038/mtna.2013.55
   PubMedGoogle Scholar
• McLachlan G, Baker A, Tennant P, et al. Optimizing aerosol gene delivery and expression in the ovine lung. Mol Ther. 2007;15(2):348–354. doi: 10.1038/sj.mt.6300058
   PubMed Web of Science ®Google Scholar
• Legere RM, Cohen ND, Poveda C, et al. Safe and effective aerosolization of in vitro transcribed mRNA to the respiratory tract epithelium of horses without a transfection agent. Sci Rep. 2021;11(1):371. doi: 10.1038/s41598-020-79855-1
   PubMed Web of Science ®Google Scholar
• Driscoll KE. Intratracheal instillation as an exposure technique for the evaluation of respiratory tract toxicity: uses and limitations. Toxicol Sci. 2000;55(1):24–35. doi: 10.1093/toxsci/55.1.24
   PubMed Web of Science ®Google Scholar
• Osier M, Oberdorster G. Intratracheal inhalation vs intratracheal instillation: differences in particle effects. Fundam Appl Toxicol. 1997;40:220–227. doi: 10.1006/faat.1997.2390
   PubMedGoogle Scholar
• Yang L, Feuchtinger A, Möller W, et al. Three-dimensional quantitative co-mapping of pulmonary morphology and nanoparticle distribution with cellular resolution in nondissected murine lungs. ACS Nano. 2019;13(2):1029–1041. doi: 10.1021/acsnano.8b07524
   PubMed Web of Science ®Google Scholar
• Bush E, Nicholas A, Pei T, et al. Targeting aEnac with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis. Eur Respir J. 2018;52:p. OA514.
   Google Scholar
• Cheever TR, Berkley D, Braun S, et al. Perspectives on best practices for gene therapy programs. Hum Gene Ther. 2015;26:127–133. doi: 10.1089/hum.2014.147
   PubMed Web of Science ®Google Scholar
• Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products. Docket Number FDA-2014-D-0852. [Internet]. U.S. Departent of Health and Human Services, Food and Drug Adminstration. Center for Biologics Evaluation and Research; 2019 [cited 2023 May 18]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-and-analysis-shedding-studies-virus-or-bacteria-based-gene-therapy-and-oncolytic-products
   Google Scholar
• U.S. Pharmacopeia. General chapter, <601> inhalation and nasal Drug products: aerosols, sprays, and powders - performance quality tests. USP-NF. Rockville (MD): Untied States Pharmacopeia; 2023.
   Google Scholar
• U.S. Pharmacopeia. General chapter, <1601> products for nebulization - characterization tests. USP-NF. Rockville (MD): Untied States Pharmacopeia; 2023.
   Google Scholar
• Cipolla D, Wu H, Gonda I, et al. Aerosol performance and stability of liposomes containing ciprofloxacin nanocrystals. J Aerosol Med Pulm Drug Deliv. 2015;28(6):411–422. doi: 10.1089/jamp.2015.1241
   PubMed Web of Science ®Google Scholar
• European Pharmacopeia. Ph Eur 9.8 general chapter 2.9.44 preparations for nebulization - characterization. Strasbourg (France): Directorate for the Quality of Medicines and HealthCare of the Council of Europe (EDQM); 2019.
   Google Scholar
• Li B, Manan RS, Liang S-Q, et al. Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing. Nat Biotechnol. 2023. doi: 10.1038/s41587-023-01679-x
   Web of Science ®Google Scholar